Clay B. Siegall

Insider Reports History

Location
Bothell, WA
Signature
/s/ Sandra Stoneman, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Clay B. Siegall:

Form 4 holding President & CEO, Director

Seagen Inc.

Security class
Common Stock
Shares / value
666,060
Estimated value
$152,527,740
Report date
12 May 2022
Price
$229.00
Ownership
Direct
Form 4 holding President and CEO, Director

Immunome Inc.

Security class
Common Stock
Shares / value
690,704
Estimated value
$13,586,147
Report date
27 Mar 2026
Price
$19.67
Ownership
Direct
Form 4 holding President and CEO, Director

Immunome Inc.

Security class
Employee Stock Option (right to buy)
Shares / value
800,000
Estimated value
Report date
29 Jul 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Shattuck Labs, Inc.

Security class
Warrants (Right to Buy)
Shares / value
128,054
Estimated value
Report date
25 Aug 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding President & CEO, Director

Seagen Inc.

Security class
Non-Qualified Stock Option (right to buy)
Shares / value
51,129
Estimated value
Report date
12 May 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Shattuck Labs, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
33,150
Estimated value
Report date
14 Jul 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Nurix Therapeutics, Inc.

Security class
Director Stock Option (right to buy)
Shares / value
17,500
Estimated value
Report date
05 May 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Tourmaline Bio, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
16,800
Estimated value
Report date
04 Jun 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Tourmaline Bio, Inc.

Security class
Employee Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
28 Oct 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Clay B. Siegall

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .